Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 5/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871994 | 0.81 | MME (0.37) | TAAR1IDO1SIGMAR1CTSSCTSK | |
| SCHEMBL9185293 | 0.80 | TRPA1 (0.40) | TAAR1SIGMAR1CYP2D6 | |
| SCHEMBL9701765 | 0.74 | TRPA1 (0.30) | — | |
| SCHEMBL5872189 | 0.72 | MEN1 (0.39) | TDP1 | |
| SCHEMBL6575503 | 0.72 | SIRT2 (0.31) | MAOB | |
| SCHEMBL1362259 | 0.71 | IDO1 (0.53) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL9602863 | 0.71 | CYP3A4 (0.40) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7310726 | 0.70 | IDO1 (0.39) | IDO1CYP2D6 | |
| SCHEMBL13721656 | 0.69 | TAAR1 (0.43) | TAAR1IDO1AGXTSIGMAR1MAOB | |
| SCHEMBL1513595 | 0.69 | SIGMAR1 (0.53) | TAAR1IDO1AGXTSIGMAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979693-B2 | Pyrazole derivatives-p38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1075467-B1 | PYRAZOLE DERIVATIVES AS P-38 MAP KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-20030018051-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2003-01-23 | — | — | US | disclosed |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-10-24 | — | — | US | disclosed |
| US-6444696-B1 | 1-ARYL OR HETEROARYL SUBSTITUTED 5-AMINO-4 CARBONYLPYRAZOLE DERIVATIVES; ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) LLC | 2002-09-03 | — | — | US | disclosed |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-08-01 | — | — | US | disclosed |
| EP-1218346-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-03 | — | — | EP | disclosed |
| US-6376527-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-6316466-B1 | Pyrazole derivatives P-38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| WO-2001021591-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018051-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K8 | TAAR1 3163/4885IDO1 3437/4885AGXT 2836/4885 |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | MAPK1, MAPK8, MAPKAPK2 | TAAR1 3223/4885IDO1 3154/4885AGXT 2912/4885 |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K8 | TAAR1 3163/4885IDO1 3437/4885AGXT 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.